Table 2.
The main demographic and clinical characteristics of patients included in the microarray group and in the testing group.
| Training (microarray) group | Testing group | |||
|---|---|---|---|---|
| EGF (%) | DGF (%) | EGF (%) | DGF (%) | |
| n. | 7 | 7 | 25 | 25 |
| Age (years) | 46.8 ± 11.0 | 47.8 ± 9.3 | 46.8 ± 11.0 | 47.8 ± 9.3 |
| Gender (M/F) | 4 (57.1)/3 (42.9) | 5 (71.4)/2 (28.6) | 16 (64)/9 (36) | 17 (68)/8 (32) |
| Dialysis (HD/PD) | 5 (71.4)/2 (28.6) | 6 (85.7)/1 (14.3) | 21 (84)/4 (16) | 22 (88)/3 (12) |
| Dialysis vintage (years) | 5.8 ± 5.0 | 7.3 ± 4.9 | 6.0 ± 4.9 | 7.5 ± 5.3 |
| HCV+ (n) | 1 (14.3) | 1 (14.3) | 2 (8) | 3 (12) |
| Body mass index (BMI) (kg/m2) | 22.8 ± 4.3 | 24.9 ± 4.8 | 23.7 ± 5.3 | 25.0 ± 5.9 |
| Panel reactive antibodies (%) | 6.5 ± 6.9 | 7.0 ± 8.7 | 7.7 ± 6.2 | 7.5 ± 6.9 |
| Cold ischemia time (hours) | 12.9 ± 6.4 | 13.1 ± 6.5 | 13.0 ± 6.3 | 13.2 ± 6.6 |
| Mismatches (n) | 3.4 ± 1.1 | 3.5 ± 1.2 | 3.3 ± 1.3 | 3.5 ± 1.0 |
| Cyclosporine (n) | 2 (28.6) | 2 (28.6) | 4 (16) | 4 (16) |
| Tacrolimus (n) | 4 (57.1) | 5 (71.4) | 21 (84) | 21 (84) |
| mTOR inhibitors (n) | 1 (14.3) | 0 | 0 | 1 |